EUVIMEDEUVIMED entdecken
Crossref

Curcuma longa-Derived Curcumin Nanoparticles in Experimental Models of Alzheimer’s Disease: A Formulation-Based Approach

Pasrija Kanika, Alka Patel, Bichitrananda Tripathy

Probecell Science · 2026

DOI: 10.65807/prob.sci.2025.2.2.4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Probecell Science, 2026. Verfasst von Pasrija Kanika und 2 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a neurodegenerative disorder involving the amyloid-β plaque deposition, tau pathology, synaptic dysfunction, and impairment in cognition. Despite years of research, all current treatment modalities are symptomatic rather than effective in preventing disease progression. Curcumin, a natural polyphenol extracted from the plant Curcuma longa, possesses potent antioxidant, anti-inflammatory, and anti-amyloid features, but its therapeutic application is hampered by inadequate aqueous solubility, low permeability across the blood-brain barrier (BBB) and poor systemic bioavailability. The goal of this study is to innovate and evaluate the neuroprotection of curcumin-loaded polymeric nanoparticles in Alzheimer\'s disease experimental models. The particle size of formulation F6 was optimal, the polydispersity index was minimised, the efficiency of encapsulation maximised, and a long-term drug release profile was demonstrated. Pharmacological studies in vivo revealed that curcumin nanoparticles significantly improved cognitive function, compared to free curcumin, as evidenced by Morris’s water maze, Y-maze, and novel object recognition tests. Histopathological examination confirmed a significant reduction in amyloid plaque burden and a preserved neuronal architecture in the nanoparticle-treated group. Conclusion: Curcumin administered via nanoparticles would be an effective multi-targeted therapeutic approach against AD.

Zitieren

APA

Kanika, P., Patel, A., & Tripathy, B. (2026). Curcuma longa-Derived Curcumin Nanoparticles in Experimental Models of Alzheimer’s Disease: A Formulation-Based Approach. Probecell Science. https://doi.org/10.65807/prob.sci.2025.2.2.4

Vancouver

Kanika P, Patel A, Tripathy B. Curcuma longa-Derived Curcumin Nanoparticles in Experimental Models of Alzheimer’s Disease: A Formulation-Based Approach. Probecell Science. 2026. doi:10.65807/prob.sci.2025.2.2.4

BibTeX
@article{Kanika2026,
  author = {Kanika, Pasrija and Patel, Alka and Tripathy, Bichitrananda},
  title = {Curcuma longa-Derived Curcumin Nanoparticles in Experimental Models of Alzheimer’s Disease: A Formulation-Based Approach},
  journal = {Probecell Science},
  year = {2026},
  doi = {10.65807/prob.sci.2025.2.2.4}
}
Kostenlos starten →